Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma

References

• Liu Z, Klominek J. Regulation of matrix metalloprotease activity in malignant mesothelioma cell lines by growth factors. Thorax. 2003;58(3):198–203. doi:10.1136/thorax.58.3.19812612292
   PubMed Web of Science ®Google Scholar
• Szulkin A, Nilsonne G, Mundt F, et al. Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapy. PLoS One. 2013;8(6):e65903. doi:10.1371/journal.pone.006590323840376
   PubMed Web of Science ®Google Scholar
• Ray M, Kindler HL. Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest. 2009;136(3):888–896. doi:10.1378/chest.08-266519736192
   PubMed Web of Science ®Google Scholar
• Lu S, Wang J. The resistance mechanisms of proteasome inhibitor bortezomib. Biomark Res. 2013;1(1):13. doi:10.1186/2050-7771-1-1324252210
   PubMedGoogle Scholar
• Chitra S, Nalini G, Rajasekhar G. The ubiquitin proteasome system and efficacy of proteasome inhibitors in diseases. Int J Rheum Dis. 2012;15(3):249–260. doi:10.1111/j.1756-185X.2012.01737.x22709487
   PubMed Web of Science ®Google Scholar
• Jones RJ, Bjorklund CC, Baladandayuthapani V, Kuhn DJ, Orlowski RZ. Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA. Mol Cancer Ther. 2012;11(10):2243–2253. doi:10.1158/1535-7163.MCT-12-013522933706
   PubMed Web of Science ®Google Scholar
• Matondo M, Bousquet-Dubouch MP, Gallay N, et al. Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: a correlation with the proteasome status. Leuk Res. 2010;34(4):498–506. doi:10.1016/j.leukres.2009.09.02019811823
   PubMed Web of Science ®Google Scholar
• O’Brien ME, Gaafar RM, Popat S, et al. Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052). Eur J Cancer. 2013;49(13):2815–2822. doi:10.1016/j.ejca.2013.05.00823791541
   PubMed Web of Science ®Google Scholar
• Fennell DA, McDowell C, Busacca S, et al. Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma. J Thorac Oncol. 2012;7(9):1466–1470. doi:10.1097/JTO.0b013e318260dfb922895144
   PubMed Web of Science ®Google Scholar
• Christoph DC, Eberhardt WE. Systemic treatment of malignant pleural mesothelioma: new agents in clinical trials raise hope of relevant improvements. Curr Opin Oncol. 2014;26(2):171–181. doi:10.1097/CCO.000000000000005324441503
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–404. doi:10.1158/2159-8290.CD-12-009522588877
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1. doi:10.1126/scisignal.200408823550210
   PubMed Web of Science ®Google Scholar
• Galateau-Salle F, Churg A, Roggli V, Travis WD; World Health Organization Committee for Tumors of the P. The 2015 World Health Organization classification of tumors of the Pleura: advances since the 2004 classification. J Thorac Oncol. 2016;11(2):142–154. doi:10.1016/j.jtho.2015.11.00526811225
   PubMed Web of Science ®Google Scholar
• Patriarca S, Ferretti S, Zanetti R. [TNM Classification of malignant tumours - Eighth edition: which news?]. Epidemiol Prev. 2017;41(2):140–143. doi:10.19191/EP17.2.P140.03428627156
   PubMed Web of Science ®Google Scholar
• Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004;15(2):257–260. doi:10.1093/annonc/mdh05914760119
   PubMed Web of Science ®Google Scholar
• Walter RF, Mairinger FD, Wohlschlaeger J, et al. FFPE tissue as a feasible source for gene expression analysis–a comparison of three reference genes and one tumor marker. Pathol Res Pract. 2013;209(12):784–789. doi:10.1016/j.prp.2013.09.00724156825
   PubMed Web of Science ®Google Scholar
• Mairinger FD, Walter RF, Theegarten D, et al. Gene Expression Analysis of the 26S Proteasome Subunit PSMB4 Reveals Significant Upregulation, Different Expression and Association with Proliferation in Human Pulmonary Neuroendocrine Tumours. J Cancer. 2014;5(8):646–654. doi:10.7150/jca.995525157275
   PubMed Web of Science ®Google Scholar
• Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55(4):611–622. doi:10.1373/clinchem.2008.11279719246619
   PubMed Web of Science ®Google Scholar
• Walter RF, Zarogoulidis P, Mairinger FD, et al. Cell viability of fibroblasts to pifenidone and sirolimus: a future concept for drug eluting stents. Int J Pharm. 2014;466(1–2):38–43. doi:10.1016/j.ijpharm.2014.03.00324607204
   PubMedGoogle Scholar
• Astoul P, Roca E, Galateau-Salle F, Scherpereel A. Malignant pleural mesothelioma: from the bench to the bedside. Respiration. 2012;83(6):481–493. doi:10.1159/00033925922710421
   PubMed Web of Science ®Google Scholar
• Kontopodis E, Kotsakis A, Kentepozidis N, et al. A phase II, open-label trial of bortezomib (VELCADE((R))) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer. Cancer Chemother Pharmacol. 2016;77(5):949–956. doi:10.1007/s00280-016-2997-726994909
   PubMed Web of Science ®Google Scholar
• Konac E, Varol N, Kiliccioglu I, Bilen CY. Synergistic effects of cisplatin and proteasome inhibitor bortezomib on human bladder cancer cells. Oncol Lett. 2015;10(1):560–564. doi:10.3892/ol.2015.325026171069
   PubMed Web of Science ®Google Scholar
• Miyamoto Y, Nakagawa S, Wada-Hiraike O, et al. Sequential effects of the proteasome inhibitor bortezomib and chemotherapeutic agents in uterine cervical cancer cell lines. Oncol Rep. 2013;29(1):51–57. doi:10.3892/or.2012.207223064281
   PubMed Web of Science ®Google Scholar
• Yerlikaya A, Altikat S, Irmak R, Cavga FZ, Kocacan SA, Boyaci I. Effect of bortezomib in combination with cisplatin and 5fluorouracil on 4T1 breast cancer cells. Mol Med Rep. 2013;8(1):277–281. doi:10.3892/mmr.2013.146623660746
   PubMed Web of Science ®Google Scholar
• Mairinger FD, Walter RF, Ting S, et al. Mdm2 protein expression is strongly associated with survival in malignant pleural mesothelioma. Future Oncol. 2014;10(6):995–1005. doi:10.2217/fon.13.26124941985
   PubMed Web of Science ®Google Scholar
• Walter RF, Mairinger FD, Ting S, et al. MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53. Br J Cancer. 2015;112(5):883–890. doi:10.1038/bjc.2015.2725668009
   PubMed Web of Science ®Google Scholar
• Nicholson J, Neelagandan K, Huart AS, Ball K, Molloy MP, Hupp T. An iTRAQ proteomics screen reveals the effects of the MDM2 binding ligand Nutlin-3 on cellular proteostasis. J Proteome Res. 2012;11(11):5464–5478. doi:10.1021/pr300698d23039052
   PubMed Web of Science ®Google Scholar
• Tabe Y, Sebasigari D, Jin L, et al. MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma. Clin Cancer Res. 2009;15(3):933–942. doi:10.1158/1078-0432.CCR-08-039919188164
   PubMed Web of Science ®Google Scholar
• Jin L, Tabe Y, Kojima K, et al. MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma. Cancer Lett. 2010;299(2):161–170. doi:10.1016/j.canlet.2010.08.01520850924
   PubMed Web of Science ®Google Scholar